Prostate Cancer Prevention

  • Jack Cuzick
  • Mangesh A. Thorat

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Lars Holmberg, Mieke Van Hemelrijck
    Pages 1-7
  3. Andrea Discacciati, Alicja Wolk
    Pages 27-37
  4. Howard L. Parnes, Otis W. Brawley, Lori M. Minasian, Leslie G. Ford
    Pages 73-77
  5. Bernd J. Schmitz-Dräger, Oliver Schöffski, Michael Marberger, Sevim Sahin, Hans-Peter Schmid
    Pages 79-91
  6. Cristina Bosetti, Valentina Rosato, Silvano Gallus, Carlo La Vecchia
    Pages 93-100
  7. Stefan Aufderklamm, Florian Miller, Anastasia Galasso, Arnulf Stenzl, Georgios Gakis
    Pages 101-108
  8. Frank L. Meyskens Jr., Anne R. Simoneau, Eugene W. Gerner
    Pages 115-120
  9. Howard L. Parnes, Margaret G. House, Joseph A. Tangrea
    Pages 121-131

About this book


Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely.   A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers. ​


Biomarkers Chemoprevention Early Detection Prostate Cancer Risk-prevention

Editors and affiliations

  • Jack Cuzick
    • 1
  • Mangesh A. Thorat
    • 2
  1. 1.Centre for Cancer PreventionWolfson Institute of Preventive Medicine Queen Mary University of LondonLondonUnited Kingdom
  2. 2.Centre for Cancer PreventionWolfson Institute of Preventive Medicine Queen Mary University of LondonLondonUnited Kingdom

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2014
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-3-642-45194-2
  • Online ISBN 978-3-642-45195-9
  • Series Print ISSN 0080-0015
  • Series Online ISSN 2197-6767
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology